Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2102-2107

  Delgrange, Etienne ^a   Trouillas, Jacqueline ^d   Maiter, Dominique ^c   Donckier, Julian ^a   Tourniaire, Jacques ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b INSERM   (France)

^c Hôpital Saint Luc   (Belgium)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROLACTIN;

ADULT; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BROMOCRIPTINE; CELL DIVISION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 0030789239     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2102     Document Type: Article

References (35)

1. Nabarro JDN. 1982 Pituitary prolactinomas. Clin Endocrinol (Oxf). 17:129-155.
2. Mindermann T, Wilson CB. 1494 Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf). 41:359-364.
3. Somma M, Beauregard H, Rasio E. 1981 Le prolactinome chez l'homme: évaluation préopératoire de 40 patients. Neurochirurgie. 27:37-34.
4. Eversmann T, Eichinger R, Fahlbusch R, Rjosk HK, von Werder K. 1981 Die hyperprolaktinämie beim mann: klinik and therapie. Schweitz Med Wochenschr. 111:1782-1789.
5. Dupuy M, Derome PJ, Peillon F, et al. 1984 L'adénome à prolactine chez l'homme: étude pré- et post-opératoire de 80 cas. Sem Hop Paris. 60:2943-2954.
6. Hulling AL, Muhr C, Lundberg PO, Werner S. 1985 Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Stand. 217:1111-109.
7. Berezin M, Shimon I, Hadani M. 1945 Prolactinoma in 53 men: clinical characteristics and modes of treatment. J Endocrinol Invest. 18:436-441.
8. Cohen LM, Greenberg DB, Murray GB. 1984 Neuropsychiatric presentation of men with pituitary tumors (the "tour A's"). Psychosomatics. 25:925-928.
9. Jackson JA, Kleerekoper M, Parfitt AM. 1986 Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann Intern Med. 105:543-545.
10. Cook RJ, Uttley D, Wilkins PR, Archer DJ, Bell BA. 1994 Prolactinomas in men masquerading as invasive skull base tumours. Br J Neurosurg. 8:51-55.
11. St Jean E, Blain F, Comtois R. 1996 High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf). 44:305-309.
12. Spark RF, Wills CA, O'Reilly G, Ransil BJ, Bergland R. 1982 Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet. 2:129-132.
13. Gimenez-Roqueplo AP, Dupuy M, Delalande O, et al. 1992 Le microadenome à prolactine chez l'homme. Ann Med Intern. 143:94-97.
14. Landolt AM. 1996 Growth of pituitary adenomas, malignant adenomas. In: Landolt AM, Vanee ML, Reilly PL, eds. Pituitary adenomas, 1st ed. Edinburgh: Churchill Livingstone; 73-82.
15. Molitch ME. 1995 Prolactinoma. In: Melmed S, ed. The pituitary, 1st ed. Oxford: Blackwell; 443-477.
16. Leonard MP, Nickel CJ, Marales A. 1989 Hyperprolactinemia and impotence: why, when and how to investigate. J Urol. 142:992-994.
17. Guay AT, Sabharwal P, Varma S, Malarkay WB. 1496 Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactine-mia. J Clin Endocrinol Metab. 81:2512-2514.
18. Cunnah D, Besser M. 1991 Management of prolactinomas. Clin Endocrinol (Oxf). 34:231-235.
19. Miyai K, Ichihara K, Kondo K, Mori S. 1486 Asymptomatic hyperprolactinemia and prolactinoma in the general population-mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf). 25:549-554.
20. Davis JRE, Sheppard MC, Heath DA. 1990 Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med. 275:227-238.
21. Saeger W, Lübke D. 1996 Pituitary carcinomas. Endocr Pathol. 7:21-35.
22. Assies J, Verhoeff NPLG, Bosch DA, Hofland LJ. 1993 Intracranial dissemination of a macroprolactinoma. Clin Endocrinol (Oxf). 38:539-546.
23. Gollard R, Kosty M, Cheney C, Copeland B, Bordin G. 1495 Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. Cancer 76:1814-1820.
24. Hsu DW, Hakim F, Biller BMK, et al. 1993 Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 78:753-761.
25. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T. 1992 Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase 224 monoclonal antibodies, bromocleoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol. 84:178-183.
26. Knosp E, Kitz K, Perneczky A. 1989 Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 25:927-930.
27. Landolt AM, Shibata T, Kleihues. 1987 Growth rate of human pituitary adenomas. J Neurosurg. 67:803-806.
28. Candour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L. 1995 Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol. 8:160-164.
29. Calle-Rodrigue R, Scheithauer BW, Lloyd RV, et al. 1996 Prolactinomas: a clinicopathologic and proliferation marker study [Abstract]. J Endocrinol Invest. 19:46.
30. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W. 1995 Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy (case report). J Neurosurg. 82:886-890.
31. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. 1992 Prolactinomas and resistance to dopamine agonists. Horm Res. 38:84-89.
32. Molitch ME, Elton RL, Blackwell RE, et al. 1985 Bromocripeine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 60:698-705.
33. Bevan JS, Webster J, Burke W, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:220-240.
34. Maraschini C, Moro M, Masala A, et al. 1991 Chronic treatment with Parlodel LAR of patients with prolactin-secreting tumors. Different responsiveness of micro-and macroprolactinomas. Acta Endocrinol (Copenh). 125:494-501.
35. Delgrange E, Maiter D, Donckier J. 1996 Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol. 134:454-456.